{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:48:51Z","timestamp":1782380931604,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To explore the clinical application of a population pharmacokinetics (PPK) model of vancomycin in patients with hematological diseases and neutropenia. Patients with hematological diseases and neutropenia were included in the PPK model study. Nonlinear mixed effect modeling approach (NONMEM) was used for model establishment. Monte Carlo simulation was carried out. A total of 74 patients were divided into model group and non\u2010model group for clinical application research. The model group was given the initial dose of 1g q8h, and the non\u2010model group was given 1g q12h as an empiric initial dosage. The follow\u2010up dose adjustments were made according to the concentration results. This two\u2010compartment model showed good stability and accuracy. The first trough concentration (<jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>) and the compliance rate of the first <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> were much higher in the model group than that in the non\u2010model group (14.30\u00a0\u00b1\u00a04.73\u00a0\u03bcg\/ml and 59.38% vs. 8.02\u00a0\u00b1\u00a02.61\u00a0\u03bcg\/ml, 35.71%). Less patients needed dose adjustments and fewer adjustment times in the model group than those in the non\u2010model group (12.50% and 0.13\u00a0\u00b1\u00a00.34 times vs. 50.00% and 0.61\u00a0\u00b1\u00a00.66 times). This suggested that for those patients who had a Creatinine clearance rate (CLCR)\u00a0\u2265\u00a090\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, the initial dose of 1g q8h may help to reach the target <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> (10\u223c20\u00a0\u03bcg\/ml) quickly. It also helped to reduce the times and number of patients who need dose adjustments. Our PPK model of vancomycin in patients with hematologic diseases and neutropenia can be used to shorten the time to reach the target concentration and reduce the number of dose adjustments.Clinical trial registration: Not applicable (Retrospective study).<\/jats:p>","DOI":"10.1002\/bdd.2303","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T17:03:11Z","timestamp":1634317391000},"page":"427-434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia"],"prefix":"10.1002","volume":"42","author":[{"given":"Xiangjun","family":"Fu","sequence":"first","affiliation":[{"name":"Hematological Department Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-2228","authenticated-orcid":false,"given":"Liangmo","family":"Lin","sequence":"additional","affiliation":[{"name":"Pharmacy Department Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[{"name":"Hematological Department Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[{"name":"Hematological Department Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University  Haikou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"issue":"8","key":"e_1_2_10_2_1","first-page":"561","article-title":"Chinese expert consensus on clinical application of vancomycin (2011 Edition)","volume":"30","author":"Chen B. Y.","year":"2011","journal-title":"Chinese Journal of New Drugs and Clinical Medicine"},{"issue":"6","key":"e_1_2_10_3_1","first-page":"428","article-title":"American Society of infectious diseases clinical practice guidelines for the treatment of methicillin \u2013 Resistant Staphylococcus aureus infections in adults and children","volume":"11","author":"Chen C. H.","year":"2011","journal-title":"Chinese Journal of Infection and Chemotherapy"},{"issue":"11","key":"e_1_2_10_4_1","first-page":"1","article-title":"Therapeutic drug monitoring of vancomycin: A guideline of the division of therapeutic drug monitoring","volume":"71","author":"Chinese Pharmacological Society","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"12","key":"e_1_2_10_5_1","first-page":"969","article-title":"Guidelines for clinical use of antibiotics in Chinese patients with neutropenia and fever (2020 Edition)","volume":"41","author":"Chinese Society of Hematology. Chinese Medical Association","year":"2020","journal-title":"Chinese Journal of Hematology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.12.021"},{"issue":"11","key":"e_1_2_10_7_1","first-page":"641","article-title":"Chinese expert consensus on clinical dosage of vancomycin","volume":"30","author":"Expert Group on clinical Dosage of Vancomycin","year":"2012","journal-title":"Chinese Journal of Infectious Diseases"},{"issue":"5","key":"e_1_2_10_8_1","first-page":"487","article-title":"Clinical characteristics and influencing factors of vancomycin concentration in patients with hematologic diseases","volume":"20","author":"Fu X. J.","year":"2020","journal-title":"Chinese Journal of Infection and Chemotherapy"},{"issue":"1","key":"e_1_2_10_9_1","first-page":"104","article-title":"Development of decision support system for individual administration of vancomycin","volume":"53","author":"Gao Y. C.","year":"2018","journal-title":"Acta Pharmaceutica Sinica"},{"issue":"1","key":"e_1_2_10_10_1","first-page":"30","article-title":"Development and application of individualized dose software of vancomycin based on group pharmacokinetic model","volume":"26","author":"Guo X. Z.","year":"2021","journal-title":"Chinese Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112008"},{"issue":"1","key":"e_1_2_10_12_1","first-page":"12","article-title":"Interpretation of China vancomycin treatment drug monitoring Guide (2020 Update Edition)","volume":"19","author":"He N.","year":"2021","journal-title":"Journal of Clinical Drug Therapy"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000270"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211402107"},{"key":"e_1_2_10_15_1","first-page":"1","article-title":"Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations","volume":"00420","author":"Joaguim F.","year":"2018","journal-title":"Pharmacology Research and Perspectives"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7101(94)90114-7"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu110"},{"key":"e_1_2_10_18_1","first-page":"1","article-title":"Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia","volume":"08","author":"Lin L.","year":"2021","journal-title":"Chinese Journal of Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202835"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13363"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0599-4"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01029.x"},{"issue":"6","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic monitoring of vancomycin for serious methicillin\u2010resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health\u2010system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak M. J.","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"e_1_2_10_24_1","first-page":"354","article-title":"Systematic study on population pharmacokinetic model of vancomycin","volume":"36","author":"Wang C. H.","year":"2020","journal-title":"Chinese Journal of Clinical Pharmacology"},{"issue":"1","key":"e_1_2_10_25_1","first-page":"12","article-title":"Study on neutropenia complicated with infection in patients with hematological malignancies","volume":"3","author":"Zhang L.","year":"2018","journal-title":"Clinical Research and Practice"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bdd.2303","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:18:54Z","timestamp":1693225134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/bdd.2303"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2303","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"2021-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}